about
A Role for Low Density Lipoprotein Receptor-Related Protein 1 in the Cellular Uptake of Tissue Plasminogen Activator in the LungsRecombinant DNA and surgerySafety of prolonged, repeated administration of a pulmonary formulation of tissue plasminogen activator in miceRenal artery embolism: thrombolysis with recombinant tissue-type plasminogen activator.Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbitsLumenal protein within secretory granules affects fusion pore expansionRole of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator.Thrombolytic therapy for the treatment of acute pulmonary embolism."Brain attack": an indication for thrombolysis?The majority of type 1 plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator.Tissue plasminogen activator in the treatment of superior vena caval thrombosis associated with parenteral nutritionSecretion of tissue-type plasminogen activator and plasminogen activator inhibitor by Rickettsia conorii- and Rickettsia rickettsii-infected cultured endothelial cells.S-nitrosylation of tissue-type plasminogen activator confers vasodilatory and antiplatelet properties on the enzymeThe use of thrombolytic therapy in pregnancy.A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivoAssessment of endothelial dysfunction.Platelets and fibrinolysis.A lethal phenotype associated with tissue plasminogen deficiency in humans.Thrombolytic therapy for cerebral infarction.S-nitrosylation of proteins: a new insight into endothelial cell function regulated by eNOS-derived NO.Production, regulation and role of nitric oxide in glial cells.Induction of uPA release in human peripheral blood lymphocytes by [deamino-Cysl,D-Arg8]-vasopressin (dDAVP).Slow fusion pore expansion creates a unique reaction chamber for co-packaged cargo.Targeting therapeutics to endothelium: are we there yet?Pharmacological approaches to the treatment and prevention of aphasia
P2860
Q28603536-8301C0C2-9FC7-449D-8F73-7B06F17B4AF9Q28768566-CE4145D6-F9A3-46DC-A306-F6F01440C5D7Q33653355-E59AE2C9-A28E-4052-A096-4E78B152B927Q33782679-7FC00C13-B2B4-45D6-ACF3-CA428AE1919CQ33848439-5B99E3C2-6CC7-4FDF-82F8-A87ECEF308AEQ33990912-60FF90A7-CD81-44DE-8BA6-59C9FDE1A91BQ34308795-969D4B24-C402-4D99-9E7E-645753F51253Q34714536-D2BFB1FC-FEC0-4A6C-9733-22C36BB0BB94Q36215665-B4631D60-FFCD-480E-A007-447C381FD18FQ36222413-2A98EB2E-D466-42B1-A161-555C39ED729FQ36718095-B9804659-7450-4C40-B514-6B173F053088Q36986388-E0335015-8DA7-46BF-B6E9-6109634283E7Q37178111-327FF627-0B90-4D9F-93CD-838545B94763Q37275338-B167A3DB-7D71-4BEE-9E96-3B8F4D8D4382Q37625157-CAFAA2C4-A112-41AF-91A9-1C2FB6069B7BQ37732250-51930F6F-0D7E-4A86-A0B0-B794C1CEE735Q37806238-EA24DB90-3F0C-464C-9AE2-13B8A326BFE4Q40650822-69314DFA-C50D-4942-A957-D40871C54378Q41165964-F3CDAD32-36C3-4907-9B8D-0B3E21D97544Q42232104-BF4FA14E-2636-441A-A1A5-B5B470832051Q42981988-D6D63BB7-4506-4002-86E5-FCEDF9E891CEQ44938036-05AC6FCB-31E0-4BAF-8956-FB6B0C573723Q46310573-DFECDDD0-8208-4D5A-BC0C-2D92F920A190Q47250590-CB5DCD9B-425B-45AC-B34A-52ADD1BE74E8Q58255428-9C9942BB-5369-4AC7-9005-4F4271B44CEA
P2860
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Tissue plasminogen activator.
@en
Tissue plasminogen activator.
@nl
type
label
Tissue plasminogen activator.
@en
Tissue plasminogen activator.
@nl
prefLabel
Tissue plasminogen activator.
@en
Tissue plasminogen activator.
@nl
P1476
Tissue plasminogen activator.
@en
P2093
Braunwald E
Loscalzo J
P304
P356
10.1056/NEJM198810063191407
P407
P577
1988-10-01T00:00:00Z